生物相容性腹膜透析液与远期腹膜溶质转运变化
基于多国前瞻性全球液体研究,分析366例腹膜透析患者,其中71例全程使用生物相容性透析液。生物相容性透析液组平均调整后透析液-血浆肌酐比为0.67,标准液组为0.72(P=0.02);标准液组腹膜溶质转运率持续上升,生物相容性液组2年后趋于平台;标准液组腹膜炎发作时溶质转运率每发作增加0.020(95%CI 0.01-0.03),生物相容性液组无变化(-0.014;95%CI -0.03至<0.01)。
要点
- 生物相容性透析液组调整后D/P肌酐比低于标准液组(0.67 vs 0.72,P=0.02)。
- 标准液组腹膜溶质转运率随透析时间持续上升,生物相容性液组2年后趋于平台。
- 标准液组腹膜炎发作后溶质转运率每发作增加0.020,生物相容性液组无此变化。
核心结论
- 不同透析液类型下腹膜溶质转运率的时间变化模式不同,生物相容性透析液可能避免腹膜炎相关的溶质转运增加。
研究设计与样本
- 多国前瞻性全球液体研究,纳入366例腹膜透析患者,其中71例全程使用生物相容性透析液。
- 要求至少3次腹膜溶质转运率测量且距腹膜透析开始>2个月。
- 生物相容性液组随访7.5年(中位2.3年,IQR 1.8-3.6),标准液组随访12.8年(中位3.2年,IQR 1.9-4.3)。
- 采用随机截距/斜率多水平模型,调整中心效应、透析液葡萄糖浓度、基线透析液IL-6、艾考糊精使用、残余肾功能和腹膜炎。
主要发现
- 生物相容性液组平均调整后透析液-血浆肌酐比为0.67,标准液组为0.72(P=0.02)。
- 标准液组腹膜溶质转运率在2个月至4年间持续增加,生物相容性液组2年后趋于平台。
- 标准液组腹膜炎每发作一次,腹膜溶质转运率增加0.020(95%CI 0.01-0.03);生物相容性液组无变化(-0.014;95%CI -0.03至<0.01)。
- 上述变化独立于基线炎症和时变预测因素。
临床怎么用
- 长期腹膜透析患者选用生物相容性透析液可能减缓腹膜溶质转运率上升。
- 使用标准液的患者发生腹膜炎后需关注腹膜溶质转运率增加。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8-3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9-4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis. RESULTS: Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (P=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (-0.014; 95% confidence interval, -0.03 to <0.01). CONCLUSIONS: These data suggest that a different temporal pattern in changes in peritoneal solute transport rate occurs during the course of peritoneal dialysis according to solution type and that patients using biocompatible solutions may avoid the increase in solute transport associated with peritonitis.
引用
- Elphick EH, Teece L, Chess JA, et al. Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. Clin J Am Soc Nephrol. 2018. PMID: 30171050. doi:10.2215/CJN.02380218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。